Literature DB >> 30815678

Children of a lesser god: exclusion of chronic kidney disease patients from clinical trials.

Carmine Zoccali1, Peter J Blankestijn2, Annette Bruchfeld3, Giovambattista Capasso4, Danilo Fliser5, Denis Fouque6, Dimitrios Goumenos7, Markus Ketteler8, Ziad Massy9, Ivan Rychlık10, Maria Jose Soler11, Kate Stevens12, Goce Spasovski13, Christoph Wanner14.   

Abstract

The exclusion of chronic kidney disease (CKD) patients from clinical trials-particularly cardiovascular trials-remains a long-standing, unsolved problem, which prevents the optimization of clinical care in these patients. The situation recalls the insufficient recruitment of women in cardiovascular trials until the 1980s, a problem that was only resolved following regulatory interventions. Regulatory agencies are in a unique position to promote recruitment of CKD patients in clinical trials. The main stakeholders, namely patients' associations and scientific societies, should make major lobbying efforts to persuade these agencies that the issue is an absolute public health priority.
© The Author(s) 2019. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  CKD; cardiovascular; clinical trial; diabetes mellitus; guidelines

Mesh:

Year:  2019        PMID: 30815678     DOI: 10.1093/ndt/gfz023

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  10 in total

Review 1.  Opportunities and challenges in using real-world data for health care.

Authors:  Vivek A Rudrapatna; Atul J Butte
Journal:  J Clin Invest       Date:  2020-02-03       Impact factor: 14.808

2.  Understanding and Overcoming the Challenges Related to Cardiovascular Trials Involving Patients with Kidney Disease.

Authors:  Julie H Ishida; Cynthia Chauhan; Barbara Gillespie; Ken Gruchalla; Peter A McCullough; Susan Quella; Alain Romero; Patrick Rossignol; David C Wheeler; Meaghan A Malley; Melissa West; Charles A Herzog
Journal:  Clin J Am Soc Nephrol       Date:  2021-04-23       Impact factor: 10.614

Review 3.  Unraveling Cardiovascular Risk in Renal Patients: A New Take on Old Tale.

Authors:  Michele Provenzano; Giuseppe Coppolino; Luca De Nicola; Raffaele Serra; Carlo Garofalo; Michele Andreucci; Davide Bolignano
Journal:  Front Cell Dev Biol       Date:  2019-12-03

Review 4.  Sodium-glucose cotransporter 2 inhibition: towards an indication to treat diabetic kidney disease.

Authors:  Jose Luis Górriz; Juan F Navarro-González; Alberto Ortiz; Ander Vergara; Julio Nuñez; Conxita Jacobs-Cachá; Alberto Martínez-Castelao; Maria Jose Soler
Journal:  Nephrol Dial Transplant       Date:  2020-01-01       Impact factor: 5.992

5.  Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial.

Authors:  Christoph Wanner; Mark E Cooper; Odd Erik Johansen; Robert Toto; Julio Rosenstock; Darren K McGuire; Steven E Kahn; Egon Pfarr; Sven Schnaidt; Maximilian von Eynatten; Jyothis T George; Nicholas D Gollop; Nikolaus Marx; John H Alexander; Bernard Zinman; Vlado Perkovic
Journal:  Clin Kidney J       Date:  2021-01-17

6.  Providing diabetes education to patients with chronic kidney disease: A survey of diabetes educators in Ontario, Canada.

Authors:  Kristin K Clemens; Alexandra M Ouédraogo; Selina L Liu; Paulina Bleah; Amanda Mikalachki; Tamara Spaic
Journal:  J Multimorb Comorb       Date:  2021-12-13

Review 7.  Pharmacoepidemiology for nephrologists (part 1): concept, applications and considerations for study design.

Authors:  Marco Trevisan; Edouard L Fu; Yang Xu; Kitty Jager; Carmine Zoccali; Friedo W Dekker; Juan Jesus Carrero
Journal:  Clin Kidney J       Date:  2020-12-14

8.  ERACODA: the European database collecting clinical information of patients on kidney replacement therapy with COVID-19.

Authors:  Marlies Noordzij; Raphaël Duivenvoorden; Michelle J Pena; Hanne de Vries; Lyanne M Kieneker
Journal:  Nephrol Dial Transplant       Date:  2020-12-04       Impact factor: 5.992

Review 9.  The cholinergic anti-inflammatory pathway in chronic kidney disease-review and vagus nerve stimulation clinical pilot study.

Authors:  Marie Hilderman; Annette Bruchfeld
Journal:  Nephrol Dial Transplant       Date:  2020-11-01       Impact factor: 5.992

Review 10.  Evidence-based medicine-When observational studies are better than randomized controlled trials.

Authors:  Jizzo R Bosdriesz; Vianda S Stel; Merel van Diepen; Yvette Meuleman; Friedo W Dekker; Carmine Zoccali; Kitty J Jager
Journal:  Nephrology (Carlton)       Date:  2020-07-02       Impact factor: 2.506

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.